Warning letters are also not findings of guilt - the FDA's own Regulatory Procedures Manual describes them as informal and advisory communications that give companies the opportunity to correct identified issues
You have patients who are prescribed Ozempic for diabetes, same drug class, semaglutide, it's a GLP-1, right
Based on the current evidence, GLP-1RAs should be considered alongside other guideline-directed medical therapies for HFpEF when indicated for T2D or obesity
[11] Popa-Wagner, A., Agar, E., Kilic, E., Mf, D., Mc, B., Sp, O., Furkan Dasdelen, M., Er, S., Kaplan, B., Celik, S., Caglar Beker, M., Orhan, C., Tuzcu, M., Sahin, N., Mamedova, H., Sylla, S., Komorowski, J., Ojalvo, S., & Sahin, K
A Phase 2 Study of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients With Rheumatoid Arthritis Inadequately Responding to Biological Disease-Modifying Antirheumatic Drugs
95% CI, 0.63-0.96), but there was no difference between oral semaglutide and placebo in patients without prior HF (HR = 1.01